BioNexus Gene Lab (BGLC) announced the formal commencement of its 2026 Deployment Phase for the VitaGuard Minimal Residual Disease platform. This phase marks the transition of VitaGuard from a technological breakthrough into what the Company believes will be a scalable oncology infrastructure, designed to displace high-cost legacy monitoring systems throughout Southeast Asia. Initial deployments are expected to commence in select Southeast Asian medical hubs during 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGLC:
- BioNexus Gene Lab Stockholders Back Governance and Incentive Plan
- BioNexus Chemrex leadership resignations prompt governance review
- Bionexus Gene Lab completes investment in Fidelion Diagnostics
- Bionexus Gene Lab secures $500M equity facility from ARC Group
- Bionexus Gene Lab, Fidelion Diagnostics execute license for VitaGuard platform